losartan and avapro

losartan has been researched along with avapro in 211 studies

Research

Studies (211)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's34 (16.11)18.2507
2000's108 (51.18)29.6817
2010's54 (25.59)24.3611
2020's15 (7.11)2.80

Authors

AuthorsStudies
Assens, JL; Bernhart, CA; Clément, J; Ferrari, BP; Haudricourt, F; Muneaux, CF; Muneaux, YA; Perreaut, PM; Taillades, JE; Vignal, MA1
Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR1
Abbenante, G; Fairlie, DP; Leung, D1
Berellini, G; Cruciani, G; Mannhold, R1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Giridhar, R; Murumkar, P; Naik, P; Yadav, MR1
Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T1
Barton, P; Luker, T; Wenlock, MC1
Chen, ZL; Da, YJ; Jia, L; Liang, LS; Nie, YY; Tian, J; Wen, CH; Yang, XX; Zheng, H1
Chen, ZL; Da, YJ; Liang, LS; Nie, YY; Xin, T; Yan, YJ; Ye, Y; Yuan, WD1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Benachour, N; Vanderheyden, PML1
Gust, R; Obexer, P; Salcher, S; Schoepf, AM1
Foster, H; Foster, R; Philippou, H; Wilson, C1
Norman, BH1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Cazaubon, C; Chatelain, P; Christophe, B; Libon, R; Manning, A; Nisato, D1
Brunner, HR; Burnier, M; Nussberger, J; Pechère-Bertschi, A; Waeber, B1
Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D1
Bauer, JH; Reams, GP1
Cazaubon, C; Chatelain, P; Delisée, C; Dol, F; Herbert, JM; Nisato, D; Schaeffer, P1
Cazaubon, C; Chatelain, P; Delisée, C; Schaeffer, P1
Cazaubon, C; Lacour, C; Nisato, D; Roccon, A; Segondy, D1
Velasquez, MT1
Biollaz, J; Brunner, HR; Buclin, T; Burnier, M; Nussberger, J; Waeber, B1
García-Sáinz, JA; González-Espinosa, C; Martínez-Alfaro, M; Romero-Avila, MT1
Brooks, DP; Feuerstein, GZ; Ohlstein, EH; Ruffolo, RR1
Adler, E; Elliott, W; Kassler-Taub, K; Littlejohn, T; Ruddy, T1
Hällfritzsch, U; Schwarzbeck, A; Wittenmeier, KW1
Cazaubon, C; Ciccocioppo, R; Massi, M; Nisato, D; Polidori, C1
Pylypchuk, GB1
Brown, MJ1
Morsing, P1
Bunt, T2
Chung, O; Csikós, T; Unger, T1
Culman, J; Piepenburg, B; Rascher, W; Unger, T; von Heyer, C1
Brunner, HR; Burnier, M; Maillard, M; Mazzolai, L; Nussberger, J; Rossat, J1
Baan, J1
Abrahamsson, T; Adler, G; Brandt-Eliasson, U; Karp, L; Morsing, P; Ohlson, K; Renberg, L; Sjöquist, PO1
Kirk, JK1
De Backer, JP; Fierens, FL; Vanderheyden, PM; Vauquelin, G1
Kaplan, NM1
Belz, GG; Butzer, R; Kober, S; Mang, C; Mutschler, E1
Spence, JD1
Fluharty, SJ; Hines, J; Sakai, RR1
Coca, A; Giner, V1
Brunner, HR; Burnier, M; Centeno, C; Daven, V; Maillard, MP; Mazzolai, L; Nussberger, J1
Cody, RJ; Goetze, S; Graf, K; Hsueh, WA; Kawano, H; Kawano, Y; Law, RE; Schnee, J1
Petkun, W1
Benedict, C; Bunt, AM; Conlin, PR; Ribeiro, AB; Saito, I; Spence, JD; Williams, B1
Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR1
DelGrande, D; Shetty, SS1
Kiukaanniemi, K; Pelkonen, O; Taavitsainen, P1
Grossman, E; Messerli, FH; Neutel, JM1
Howes, L; Wong, W1
Fierens, FL; Vanderheyden, PM; Vauquelin, G1
Badguet, JP; Mallion, JM1
Burnier, M1
De Backer, JP; Fierens, FL; Morsing, P; Vanderheyden, PM; Vauquelin, G1
Vidt, DG1
Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA1
Ramahi, TM1
Giatas, N; Golic Grdadolnik, S; Iliodromitis, EK; Keivish, T; Kremastinos, DT; Matsoukas, J; Mavromoustakos, T; Mutule, I; Polevaya, L; Roumelioti, P; Vlahakos, DV; Zoumboulakis, P1
Balt, JC; Mathy, MJ; Nap, A; Pfaffendorf, M; van Zwieten, PA1
Coats, AJ1
Li, Q; Pfaffendorf, M; van Zwieten, PA1
Alonso, RM; Cagigal, E; González, L; Jiménez, RM1
Bloomgarden, ZT1
Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G1
Kurtzman, NA1
Atkins, RC; Cooper, ME; Gilbert, RE; Jerums, G1
Beevers, DG; Lip, GY1
Christides, D; Elisaf, M; Liberopoulos, E1
Brunner, HR; Burnier, M; Centeno, C; Maillard, MP; Nussberger, J; Würzner, G1
Akesolo, U; Alonso, RM; González, L; Jiménez, RM1
Walser, M1
Ceriello, A; Motz, E1
MacGregor, GA; Swift, PA1
Howes, LG; Tran, D1
Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, W; Hausdorf, C; Mang, C1
Doggrell, SA2
Ganado, P; Sanz, M; Tejerina, T1
Studney, D1
Schiffrin, EL1
Rapi, J1
Hasford, J; Mimran, A; Simons, WR1
Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D1
Ribeiro, AB; Zanella, MT1
Balt, JC; Nap, A; Pfaffendorf, M; Van Zwieten, PA1
Eguchi, K; Kario, K; Shimada, K1
Suzuki, H2
Allcock, NM; Graham, MR1
Bassett, ML; Fisher, AA1
Elmfeldt, D; Meredith, P; Olofsson, B1
Karpov, IuA1
Alvarez, A; Fernández-Calotti, P; Gamberale, R; Geffner, JR; Giordano, M; Nahmod, KA; Nahmod, V; Raiden, S; Salamone, G; Vermeulen, ME1
Mancini, GB1
Dikow, R; Eberhard, R1
Beilin, LJ; Croft, KD; Proudfoot, JM; Puddey, IB1
De Backer, JP; Vanderheyden, P; Vauquelin, G; Verheijen, I1
Schieffer, B; Schmidt, B1
Alföldi, S1
Terra, SG1
Bessard, G; Caron, F; Cracowski, JL; Hakim, A; Hoffmann, P; Sessa, C; Stanke-Labesque, F1
Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV1
de Jong-van den Berg, LT; de Zeeuw, D; Kruidhof, H; Postma, MJ1
Jermendy, G; Matos, L; Winkler, G1
Dominiak, P; Häuser, W1
Arthur, S; Barrish, J; Baska, RA; Baumann, J; Beyer, S; Bird, E; Carlson, K; Dickinson, K; Fadnis, L; Ferrer, P; Giancarli, M; Gu, Z; Kane, B; Kowala, MC; Macor, JE; Monshizadegan, H; Murugesan, N; Panchal, B; Perrone, M; Ryan, C; Tellew, J; Trippodo, N; Yang, Y; Zhang, D1
Ruilope, LM; Segura, J1
Daliani, I; Dimitriou, D; Kamoutsis, C; Kyrikou, I; Laggner, P; Mavromoustakos, T; Pitsas, A; Siapi, E; Zervou, M; Zoga, A; Zoumpoulakis, P1
Chambliss, ML; Foreman, BH1
Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J1
Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM1
Clasen, R; Janke, J; Kintscher, U; Schupp, M; Unger, T1
Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK1
Stumpe, KO1
Dubiel, R; Jones, M; Smith, DH1
Isreb, MA; Leehey, DJ; Marcic, S; Singh, AK; Singh, R1
Shlipak, M1
Dendorfer, A; Dominiak, P; Raasch, W; Tempel, K1
Chen, G; Dang, A; Liu, G; Song, W; Wang, B; Zhang, Y1
Pershadsingh, HA1
Feng, YQ; Nie, J; Wei, F; Zhang, M; Zhang, YF1
Fontanazza, A; Martarelli, D; Pediconi, D; Pompei, P1
Burnier, M; Zanchi, A1
Sica, DA1
Gavras, H; Ribeiro, AB1
Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO1
Boschmann, M; Engeli, S; Gorzelniak, K; Janke, J; Jordan, J; Luft, FC; Nystrom, FH; Sauma, L; Schupp, M; Sharma, AM1
Bandlow, N; Beck, S; Drexler, H; Grote, K; Kaszkin, M; Luchtefeld, M; Pfeilschifter, J; Schieffer, B; Tietge, UJ1
Al-Hiari, YM; Alhamami, OM; Shakya, AK1
Chen, GL; Dang, AM; Liu, GZ; Zhang, YH1
Bianchetti, MG; Fossali, E; Ghiglia, S; Limoni, C; Meier, CM; Salice, P; Simonetti, GD1
Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV1
Belsey, JD1
Brooke, BS; Dietz, HC; Habashi, JP; Judge, DP; Loeys, B; Patel, N1
Dal Pan, GJ; Governale, LA; Hammad, TA; McAdams, MA; Swartz, L1
Hatzitolios, A; Ntaios, G; Savopoulos, C1
Grigg, M; Harahap, Y; Lusthom, W; Prasaja, B; Sasongko, L1
Bae, SK; Cho, DY; Kim, EY; Kim, MJ; Liu, KH; Shim, EJ; Shin, JG; Shon, JH1
Falvey, H; Lowy, A; Müller, E; Nixon, RM1
Cerar, LK; Cvijic, M; Gersak, K1
Ji, HY; Lee, HS; Lee, HW; Lee, KC; Park, ES1
Alfarano, C; Cerbai, E; Failli, P; Franchi-Micheli, S; Mannucci, E; Mugelli, A; Raimondi, L1
Bähr, IN; Fleck, E; Fritzsche, J; Goebel, M; Gust, R; Hässle, PL; Kappert, K; Kaufmann, J; Kintscher, U; Ott, I; Stawowy, P; Tsuprykov, O; Unger, T1
Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J1
Kamiyama, E; Mikkaichi, T; Nakai, D; Okazaki, O; Okudaira, N1
Bramlage, P; Schindler, C1
Burnier, M; Coltamai, L; Maillard, M; Simon, A; Vogt, B1
Fox, DA; Kashihara, N; Morita, Y; Sakuta, T; Satoh, M1
Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J1
Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J1
Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J1
Fujino, M; Karnik, SS; Kiya, Y; Matsuo, Y; Miura, S; Saku, K; Tominaga, Y1
Berl, T; de Graeff, PA; de Zeeuw, D; Holtkamp, FA; Lambers Heerspink, HJ; Laverman, GD; Lewis, JB; Packham, D; Parving, HH; Remuzzi, G1
Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Oshima, K; Tsukuda, K1
Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A1
Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO1
Biskupiak, J; Qian, C; Quah, R; Ram, CV; Ramaswamy, K; Russo, PA; Ryan, A1
Bakker, SJ; Berl, T; Cooper, ME; de Zeeuw, D; Lambers Heerspink, HJ; Laverman, GD; Smink, PA1
Joffe, MM; Yang, W1
Kusunoki, H; Morishita, R; Rakugi, H; Taniyama, Y1
Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G1
Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z1
Bigagli, E; Lodovici, M; Manni, ME; Musilli, C; Raimondi, L; Zazzeri, M1
Allen, RR; Ghushchyan, V; Kaila, S; Nair, KV; Saseen, JJ1
Coresh, J; de Zeeuw, D; Dwyer, JP; Gansevoort, R; Greene, T; Inker, LA; Lambers Heerspink, HJ; Levey, AS; Mondal, H; Parving, HH; Weldegiorgis, M1
Caffrey, JL; Chang, CH; Lai, MS; Lin, JW; Wu, LC1
Addabbo, F; Carratù, MR; Iacobazzi, D; Leo, V; Montagnani, M; Potenza, MA; Sgarra, L1
Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ1
Agarwal, A; Hull, TD1
Dong, Z; Ekins, S; Polli, JE1
de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B1
Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH1
Deng, SB; Du, JL; Liu, YJ; Qiu, B; She, Q; Wang, J1
Brown, SA; Coleman, AE; Jenkins, TL; Schmiedt, CW1
de Zeeuw, D; Felix Kröpelin, T; Holtkamp, FA; L Heerspink, HJ; Packham, DK1
Anzai, N; Hamada, T; Hirota, Y; Hisatome, I; Ikeda, N; Kato, M; Kuwabara, M; Maharani, N; Mishima, M; Miyazaki, S; Mizuta, E; Ninomiya, H; Notsu, T; Ogino, K; Onohara, T; Otani, N; Sugihara, S; Yoshida, A1
Asayama, K; Haga, T; Hosaka, M; Imai, Y; Inoue, R; Kikuya, M; Mano, N; Metoki, H; Murakami, T; Obara, T; Ohkubo, T; Satoh, M1
Ah, YM; Choi, KH; Choi, YJ; Han, N; Kim, B; Kong, J; Lee, HY; Lee, JY; Oh, JM; Shin, WG; Yu, YM1
Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P1
Agbaba, D; Grujić, M; Nikolic, K; Popović, G; Popović, M1
Caltagirone, C; Cooper, GJ; Crisponi, G; Jaraquemada-Pelaez, MG; Lachowicz, JI; Nurchi, VM; Peana, M; Szewczuk, Z; Zoroddu, MA1
Brolund, L; Brolund-Spaether, K; Cascorbi, I; Culman, J; Gohlke, P; Jacob, T; Schuster, SO; Zhao, Y1
Guo, CX; Li, X; Liu, JY; Liu, SK; Liu, ZQ; Luo, M; Pei, Q; Xie, P; Yang, GP; Yin, JY; Zheng, Y; Zhou, HH1
Jóźwiak, K; Kocki, T; Targowska-Duda, KM; Turski, WA; Wnorowski, A; Zakrocka, I1
Bhalla, V; Byrd, JB; Chertow, GM1
Abdelsalam, RA; Haddad, GM; Marghany, KA1
Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM1
Kim, H; Kim, HS; Kim, JH; Lee, SH1
Chountoulesi, M; Demetzos, C; Mavromoustakos, T; Naziris, N; Ntountaniotis, D1
Daugherty, A; Franklin, MK; Howatt, DA; Lu, HS; Moorleghen, JJ; Mullick, AE; Ohno-Urabe, S; Sawada, H; Ye, D1
Bester, K; Kisielius, V; Li, R; Liang, C; Svendsen, SB1
Dantas, ASCL; de Lima, PC; de Souza, MN; Ferreira, LODS; Lima, MED; Maranho, RLDN; Monteiro, MA; Novotny, TS; Ochs, SM; Santana, DS1
Bradley, MC; Eworuke, E; Ghosh, RE; Hou, L; Jensen, PB; Lee, H; Maro, JC; Paterson, MJ; Pennap, D; Platt, RW; Pottegard, A; Rai, A; Scarnecchia, D; Shinde, M; Welburn, S; Woronow, D1
Bradley, M; Eworuke, E; Hedenmalm, K; Kurz, X; Lee, H; Quinten, C1
Liang, H; Tang, T; Xie, M1
Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG1

Reviews

60 review(s) available for losartan and avapro

ArticleYear
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
    Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship

1996
Protease inhibitors: current status and future prospects.
    Journal of medicinal chemistry, 2000, Feb-10, Volume: 43, Issue:3

    Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors

2000
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
    Bioorganic & medicinal chemistry, 2010, Dec-15, Volume: 18, Issue:24

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
    Bioorganic & medicinal chemistry letters, 2017, 08-15, Volume: 27, Issue:16

    Topics: Angiotensin II Type 1 Receptor Blockers; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kinetics; Ligands; Protein Binding; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction

2017
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
    Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20

    Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution

2020
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
    Archives of internal medicine, 1995, Jul-10, Volume: 155, Issue:13

    Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Pyridines; Quinolines; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

1995
Angiotensin II receptor blockers. A new class of antihypertensive drugs.
    Archives of family medicine, 1996, Volume: 5, Issue:6

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzothiadiazines; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diuretics; Enalapril; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Multicenter Studies as Topic; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Sodium Chloride Symporter Inhibitors; Tetrazoles

1996
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
    Kidney international. Supplement, 1996, Volume: 55

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Prodrugs; Reference Values; Tetrazoles

1996
ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:10

    Topics: Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cough; Humans; Irbesartan; Losartan; Tetrazoles

1998
Irbesartan treatment in hypertension.
    Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Enalapril; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles

1998
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
    Journal of the American Society of Nephrology : JASN, 1999, Volume: 10 Suppl 11

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Hemodynamics; Humans; Hypertension; Irbesartan; Kidney; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles

1999
Angiotensin II receptor pharmacology and AT1-receptor blockers.
    Journal of human hypertension, 1999, Volume: 13 Suppl 1

    Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Thiophenes

1999
Angiotensin-II receptor antagonists: their place in therapy.
    American family physician, 1999, Volume: 59, Issue:11

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan

1999
Angiotensin II receptor antagonists in the treatment of hypertension.
    American family physician, 1999, Sep-15, Volume: 60, Issue:4

    Topics: Algorithms; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Receptors, Angiotensin; Telmisartan; Tetrazoles; Valine; Valsartan

1999
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Revista espanola de cardiologia, 1999, Volume: 52 Suppl 3

    Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

1999
Angiotensin II antagonists for hypertension: are there differences in efficacy?
    American journal of hypertension, 2000, Volume: 13, Issue:4 Pt 1

    Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2000
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
    Archives of internal medicine, 2000, Jul-10, Volume: 160, Issue:13

    Topics: Acrylates; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Therapy, Combination; Heart; Humans; Hypertension; Imidazoles; Irbesartan; Kidney; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes

2000
Angiotensin receptor antagonists.
    Australian family physician, 2000, Volume: 29, Issue:7

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Telmisartan; Tetrazoles

2000
Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
    Journal of human hypertension, 2000, Volume: 14 Suppl 2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cattle; Cerebellum; Circadian Rhythm; Female; Heart; Humans; Hypertension; In Vitro Techniques; Irbesartan; Kinetics; Losartan; Male; Middle Aged; Prodrugs; Rabbits; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renin; Tetrazoles; Time Factors

2000
Angiotensin II type 1 receptor blockers.
    Circulation, 2001, Feb-13, Volume: 103, Issue:6

    Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Blood Pressure; Drug Design; Humans; Irbesartan; Losartan; Peptidyl-Dipeptidase A; Protein Binding; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Saralasin; Tetrazoles; Valine; Valsartan

2001
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Postgraduate medicine, 2001, Volume: 109, Issue:4

    Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; Humans; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Metabolic Clearance Rate; Patient Selection; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Valine; Valsartan

2001
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    International journal of cardiology, 2001, Volume: 79, Issue:2-3

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Valine; Valsartan

2001
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
    Journal of human hypertension, 2001, Volume: 15, Issue:12

    Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Middle Aged; Primary Prevention; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Tetrazoles; Treatment Outcome

2001
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2001, Volume: 2, Issue:3

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Irbesartan; Kidney; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles

2001
Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?
    Drug safety, 2002, Volume: 25, Issue:2

    Topics: Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles

2002
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    The Canadian journal of cardiology, 2002, Volume: 18 Suppl A

    Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Captopril; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Irbesartan; Kidney Diseases; Losartan; Prognosis; Ramipril; Tetrazoles

2002
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
    The Canadian journal of cardiology, 2002, Volume: 18 Suppl A

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biphenyl Compounds; Cilazapril; Humans; Hypertension; Irbesartan; Losartan; Perindopril; Tetrazoles

2002
[Irbesartan: a new possibility in the treatment of hypertension].
    Orvosi hetilap, 2002, May-26, Volume: 143, Issue:21

    Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2002
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Clinical therapeutics, 2002, Volume: 24, Issue:7

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Renal Circulation; Tetrazoles

2002
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Captopril; Cardiomegaly; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetic Retinopathy; Humans; Hypertension; Irbesartan; Kidney Diseases; Losartan; Practice Guidelines as Topic; Risk; Tetrazoles

2002
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:10

    Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Tetrazoles

2002
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 10

    Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Captopril; Clinical Trials as Topic; Disease Progression; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Treatment Outcome

2002
Acute pancreatitis associated with angiotensin II receptor antagonists.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:12

    Topics: Acute Disease; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Irbesartan; Losartan; Pancreatitis; Sodium Chloride Symporter Inhibitors; Tetrazoles

2002
The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
    Blood pressure, 2002, Volume: 11, Issue:5

    Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
    Kardiologiia, 2002, Volume: 42, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diastole; Diuretics; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Losartan; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Systole; Tetrazoles; Time Factors

2002
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
    The Canadian journal of cardiology, 2002, Volume: 18, Issue:12

    Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary Artery Disease; Data Interpretation, Statistical; Diabetes Mellitus; E-Selectin; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Thiophenes; Vasculitis

2002
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
    Annals of medicine, 2002, Volume: 34, Issue:7-8

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension, Renal; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles

2002
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
    Journal of medicinal chemistry, 2003, Jun-05, Volume: 46, Issue:12

    Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2

2003
[Diurnal blood pressure control in the optimal treatment of hypertension].
    Orvosi hetilap, 2003, May-04, Volume: 144, Issue:18 Suppl 1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Irbesartan; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan

2003
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
    Kardiologiia, 2003, Volume: 43, Issue:2

    Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2003
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Health Care Costs; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Treatment Outcome

2003
[Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
    Orvosi hetilap, 2003, Sep-07, Volume: 144, Issue:36

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2003
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Clinical therapeutics, 2003, Volume: 25, Issue:12

    Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Tetrazoles

2003
Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
    Current topics in medicinal chemistry, 2004, Volume: 4, Issue:4

    Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Binding Sites; Biphenyl Compounds; Calorimetry, Differential Scanning; Cell Membrane; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Magnetic Resonance Spectroscopy; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; X-Ray Diffraction

2004
Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
    The Journal of family practice, 2004, Volume: 53, Issue:3

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Humans; Irbesartan; Losartan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tetrazoles

2004
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
    Kardiologiia, 2004, Volume: 44, Issue:1

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan

2004
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Clinical therapeutics, 2004, Volume: 26 Suppl A

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan

2004
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:3

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Losartan; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Tetrazoles

2005
Diabetic nephropathy.
    Clinical evidence, 2004, Issue:12

    Topics: Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Glucose; Captopril; Diabetic Nephropathies; Humans; Irbesartan; Losartan; Tetrazoles

2004
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
    The international journal of biochemistry & cell biology, 2006, Volume: 38, Issue:5-6

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Irbesartan; Losartan; Metabolic Syndrome; PPAR gamma; Telmisartan; Tetrazoles

2006
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Journal of hypertension, 2006, Volume: 24, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Disease Progression; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles

2006
Angiotensin receptor blockers: new considerations in their mechanism of action.
    Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:5

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Hemodynamics; Humans; Irbesartan; Losartan; Sympathetic Nervous System; Tetrazoles

2006
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
    Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular System; Diabetic Nephropathies; Humans; Hypertension; Irbesartan; Kidney; Losartan; Proteinuria; Tetrazoles

2006
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
    International journal of clinical practice, 2009, Volume: 63, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2009
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:4

    Topics: Administration, Oral; Angiotensin II; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Diabetic Nephropathies; Health Care Costs; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Treatment Outcome

2010
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
    Journal of hypertension, 2011, Volume: 29, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Control Studies; Double-Blind Method; Humans; Hypertension; Irbesartan; Losartan; Neoplasms; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles

2011
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
    European heart journal, 2011, Volume: 32, Issue:12

    Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Stroke; Tetrazoles; Treatment Outcome

2011
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
    Clinical drug investigation, 2011, Volume: 31, Issue:7

    Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan

2011
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
    Clinical cardiology, 2023, Volume: 46, Issue:8

    Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essential Hypertension; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Network Meta-Analysis; Telmisartan; Tetrazoles; Valine; Valsartan

2023

Trials

24 trial(s) available for losartan and avapro

ArticleYear
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    American journal of hypertension, 1998, Volume: 11, Issue:4 Pt 1

    Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome

1998
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 33, Issue:3

    Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Humans; Irbesartan; Losartan; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Valine; Valsartan

1999
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
    Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:4

    Topics: Adult; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Irbesartan; Losartan; Male; Radioligand Assay; Reference Values; Tetrazoles; Time Factors; Valine; Valsartan

1999
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
    American journal of hypertension, 1999, Volume: 12, Issue:12 Pt 1-2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Irbesartan; Losartan; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reproducibility of Results; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents

1999
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
    Journal of hypertension, 2001, Volume: 19, Issue:10

    Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind Method; Gout; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Prospective Studies; Tetrazoles; Uric Acid

2001
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
    Clinical pharmacology and therapeutics, 2002, Volume: 71, Issue:1

    Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Irbesartan; Losartan; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2002
The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:4

    Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Irbesartan; Losartan; Male; Receptor, Angiotensin, Type 1; Reference Values; Tetrazoles; Valine; Valsartan

2000
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
    Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:2

    Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
    The American journal of cardiology, 2004, Jun-01, Volume: 93, Issue:11

    Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Brachial Artery; Double-Blind Method; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Vasodilation

2004
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2005, Volume: 5, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Monitoring, Physiologic; Olmesartan Medoxomil; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2005
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
    Journal of human hypertension, 2006, Volume: 20, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Double-Blind Method; Female; Humans; Hypertension; Hyperuricemia; Incidence; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Uric Acid

2006
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
    Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:10

    Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Child, Preschool; Female; Humans; Hypertension; Infant; Irbesartan; Losartan; Male; Proteinuria; Tablets; Tetrazoles

2006
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
    Atherosclerosis, 2007, Volume: 194, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Cells, Cultured; Coronary Artery Disease; Enzyme Activation; Enzyme Inhibitors; Female; Group II Phospholipases A2; Humans; Hypertension; Indoles; Irbesartan; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles

2007
[The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
    Zhonghua xin xue guan bing za zhi, 2006, Volume: 34, Issue:10

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Uric Acid

2006
Palatability of angiotensin II antagonists among nephropathic children.
    British journal of clinical pharmacology, 2007, Volume: 63, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Child; Child, Preschool; Female; Humans; Irbesartan; Kidney Diseases; Losartan; Male; Patient Compliance; Patient Satisfaction; Smell; Taste; Telmisartan; Tetrazoles; Valine; Valsartan

2007
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
    The New England journal of medicine, 2008, Jun-26, Volume: 358, Issue:26

    Topics: Adolescent; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aorta; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Child; Child, Preschool; Drug Therapy, Combination; Female; Heart Rate; Humans; Infant; Irbesartan; Linear Models; Losartan; Male; Marfan Syndrome; Prospective Studies; Tetrazoles; Transforming Growth Factor beta

2008
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:4

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Muscle Cells; PPAR gamma; Telmisartan; Tetrazoles

2009
Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
    Journal of hypertension, 2010, Volume: 28, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Imidazoles; Irbesartan; Kidney Tubules; Losartan; Single-Blind Method; Tetrazoles; Valine; Valsartan

2010
An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
    Journal of hypertension, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Data Interpretation, Statistical; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Middle Aged; Placebos; Proportional Hazards Models; Risk; Risk Factors; Tetrazoles; Treatment Outcome; Uric Acid

2012
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 63, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Tetrazoles

2014
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:4

    Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Individuality; Irbesartan; Kidney; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Potassium; Prospective Studies; Risk Factors; Tetrazoles; Uric Acid

2015
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:3

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Progression; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Tetrazoles

2015
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
    Journal of clinical pharmacology, 2015, Volume: 55, Issue:12

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet, Sodium-Restricted; Drug Synergism; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Young Adult

2015
Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats.
    American journal of veterinary research, 2015, Volume: 76, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cats; Cross-Over Studies; Irbesartan; Losartan; Telmisartan; Tetrazoles

2015

Other Studies

127 other study(ies) available for losartan and avapro

ArticleYear
A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
    Journal of medicinal chemistry, 1993, Oct-29, Volume: 36, Issue:22

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Female; Imidazoles; In Vitro Techniques; Irbesartan; Macaca fascicularis; Male; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Sensitivity and Specificity; Structure-Activity Relationship; Tetrazoles

1993
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
    Journal of medicinal chemistry, 2005, Jun-30, Volume: 48, Issue:13

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles

2005
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents

2011
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
    Bioorganic & medicinal chemistry letters, 2011, Jun-15, Volume: 21, Issue:12

    Topics: Acids; Albumins; Drug Design; Humans; Hydrogen-Ion Concentration; Lipids; Molecular Structure; Pharmaceutical Preparations; Protein Binding

2011
Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
    Bioorganic & medicinal chemistry, 2012, Apr-15, Volume: 20, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Dose-Response Relationship, Drug; Molecular Conformation; Molecular Structure; Rats; Rats, Inbred SHR

2012
Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
    Bioorganic & medicinal chemistry, 2012, Dec-15, Volume: 20, Issue:24

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antineoplastic Agents; Cell Line, Tumor; Humans; Hydrocarbons, Fluorinated; Hypertension; Male; Mice; Mice, Nude; Prostatic Neoplasms; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index

2014
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
    European journal of medicinal chemistry, 2020, Jun-01, Volume: 195

    Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan

2020
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
    Journal of medicinal chemistry, 2020, 11-12, Volume: 63, Issue:21

    Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Thrombosis

2020
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.
    European journal of pharmacology, 1995, Aug-04, Volume: 281, Issue:2

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Imidazoles; Irbesartan; Losartan; Male; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles; Time Factors

1995
Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1995, Volume: 26, Issue:1

    Topics: Adult; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Kidney; Kidney Tubules; Losartan; Natriuresis; Potassium; Renin-Angiotensin System; Sodium; Sodium, Dietary; Tetrazoles; Uric Acid; Vasomotor System; Water

1995
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    European journal of pharmacology, 1994, Nov-03, Volume: 264, Issue:3

    Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tolerance; Enalapril; Hypertension, Renal; Imidazoles; Injections, Intravenous; Irbesartan; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Tachycardia; Tetrazoles

1994
Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.
    European journal of pharmacology, 1994, Jan-14, Volume: 251, Issue:2-3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium; Cell Division; Cells, Cultured; Humans; Imidazoles; Iodine Radioisotopes; Irbesartan; Losartan; Mitogens; Muscle, Smooth, Vascular; Protein Binding; Tetrazoles

1994
Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436.
    European journal of pharmacology, 1993, Oct-15, Volume: 247, Issue:2

    Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Calcium; Cells, Cultured; Heart; Homeostasis; Imidazoles; Irbesartan; Kinetics; Losartan; Myocardium; Pyridines; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles

1993
Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys.
    Journal of hypertension, 1993, Volume: 11, Issue:11

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Female; Imidazoles; Irbesartan; Losartan; Macaca fascicularis; Male; Renin; Sodium, Dietary; Tetrazoles

1993
Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver.
    The Journal of endocrinology, 1997, Volume: 154, Issue:1

    Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Binding, Competitive; Biphenyl Compounds; Enzyme Activation; Guinea Pigs; Imidazoles; Irbesartan; Liver; Losartan; Male; Polymerase Chain Reaction; Pyridines; Receptors, Angiotensin; RNA, Messenger; Tetrazoles

1997
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Pharmacology, 1997, Volume: 55, Issue:5

    Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Electric Stimulation; Imidazoles; Irbesartan; Losartan; Male; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan

1997
Anaemia in dialysis patients as a side-effect of sartanes.
    Lancet (London, England), 1998, Jul-25, Volume: 352, Issue:9124

    Topics: Anemia; Antihypertensive Agents; Biphenyl Compounds; Hemoglobins; Humans; Irbesartan; Kidney Transplantation; Losartan; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Tetrazoles

1998
Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.
    European journal of pharmacology, 1998, Jul-03, Volume: 352, Issue:1

    Topics: Adrenalectomy; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood-Brain Barrier; Carbachol; Drug Evaluation; Injections, Intraventricular; Irbesartan; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Wistar; Stomach; Tetrazoles

1998
Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.
    American journal of hypertension, 1999, Volume: 12, Issue:1 Pt 1

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decision Making; Drug Labeling; Follow-Up Studies; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 2; Tetrazoles; United States; United States Food and Drug Administration

1999
Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    European journal of pharmacology, 1999, Feb-19, Volume: 367, Issue:2-3

    Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Brain; Dose-Response Relationship, Drug; Drinking; Drug Interactions; Injections, Intravenous; Injections, Intraventricular; Irbesartan; Losartan; Male; Pituitary Gland, Posterior; Rats; Rats, Wistar; Tetrazoles; Vasopressins

1999
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
    Clinical therapeutics, 1999, Volume: 21, Issue:3

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Titrimetry

1999
AT1-receptor antagonists for the treatment of chronic heart failure.
    Cardiovascular research, 1999, Volume: 41, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Captopril; Dogs; Heart Failure; Humans; Irbesartan; Losartan; Rats; Tetrazoles

1999
Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Hypertension (Dallas, Tex. : 1979), 1999, Volume: 33, Issue:6

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Proteins; Female; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Portal Vein; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles

1999
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
    European journal of pharmacology, 1999, May-14, Volume: 372, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles

1999
Efficacy of angiotensin II antagonists in hypertension.
    The Canadian journal of cardiology, 1999, Volume: 15 Suppl F

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan

1999
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
    European journal of pharmacology, 1999, Nov-12, Volume: 384, Issue:1

    Topics: Adrenal Glands; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Iodine Radioisotopes; Irbesartan; Kidney; Liver; Losartan; Male; PC12 Cells; Pituitary Gland; Pyrimidines; Radioligand Assay; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Signal Transduction; Tetrazoles

1999
Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:1 Pt 2

    Topics: Actinin; Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antigens, CD; Antihypertensive Agents; Biphenyl Compounds; Cardiomegaly; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Collagen; Fibroblasts; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Heart Ventricles; Hydralazine; Imidazoles; Integrin alphaV; Integrin beta Chains; Integrin beta1; Integrin beta3; Integrins; Irbesartan; Laminin; Losartan; Myocardium; Phosphorylation; Platelet Membrane Glycoproteins; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Up-Regulation; Vitronectin

2000
AT1-receptor blockers.
    European heart journal, 2000, Volume: 21, Issue:4

    Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Tetrazoles; Valine; Valsartan

2000
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:6

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan

2000
Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:1

    Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response Relationship, Drug; Heart; Imidazoles; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Angiotensin; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan

2000
In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
    European journal of clinical pharmacology, 2000, Volume: 56, Issue:2

    Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Irbesartan; Losartan; Microsomes, Liver; Protein Isoforms; Tetrazoles; Thiophenes; Valine; Valsartan

2000
Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
    Biochemical pharmacology, 2000, Dec-01, Volume: 60, Issue:11

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Binding Sites; Biphenyl Compounds; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles

2000
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
    Biochemical pharmacology, 2001, Feb-01, Volume: 61, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; CHO Cells; Computer Simulation; Cricetinae; Dose-Response Relationship, Drug; Inositol Phosphates; Irbesartan; Kinetics; Losartan; Models, Biological; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles

2001
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
    Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:3

    Topics: Acrylates; Angioedema; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Black or African American; Clinical Trials as Topic; Cough; Female; Humans; Imidazoles; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Sex Factors; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2001
Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
    Journal of hypertension, 2001, Volume: 19, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Captopril; Decerebrate State; Electric Stimulation; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sympathetic Nervous System; Synaptic Transmission; Telmisartan; Tetrazoles

2001
Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
    Bioorganic & medicinal chemistry, 2001, Volume: 9, Issue:6

    Topics: Acrylates; Angiotensin II; Animals; Antihypertensive Agents; Biochemistry; Biphenyl Compounds; Drug Design; Imidazoles; Irbesartan; Losartan; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Peptides, Cyclic; Rabbits; Structure-Activity Relationship; Tetrazoles; Thiophenes

2001
Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
    Journal of cardiovascular pharmacology, 2001, Volume: 38, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Electric Stimulation; Irbesartan; Losartan; Male; Mesenteric Arteries; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sympathetic Nervous System; Telmisartan; Tetrazoles; Vasoconstrictor Agents

2001
Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
    Fundamental & clinical pharmacology, 2001, Volume: 15, Issue:2

    Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Anti-Bacterial Agents; Antihypertensive Agents; Biphenyl Compounds; Endothelium, Vascular; Femoral Artery; Imidazoles; In Vitro Techniques; Irbesartan; Leucine; Losartan; Male; Peptides; Protease Inhibitors; Pyridines; Rabbits; Receptor, Angiotensin, Type 1; Renal Artery; Tetrazoles; Vasoconstrictor Agents

2001
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
    Journal of pharmaceutical and biomedical analysis, 2001, Volume: 26, Issue:3

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Hydrogen-Ion Concentration; Irbesartan; Losartan; Spectrometry, Fluorescence; Tetrazoles

2001
Angiotensin II receptor blockers and nephropathy trials.
    Diabetes care, 2001, Volume: 24, Issue:10

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Obesity; Tetrazoles; Vasodilator Agents

2001
Drug companies should not have the final say in the design of clinical trials.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 38, Issue:5

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Industry; Enalapril; Humans; Irbesartan; Losartan; Research Design; Tetrazoles

2001
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
    The Medical journal of Australia, 2001, Oct-15, Volume: 175, Issue:8

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension, Renal; Irbesartan; Kidney; Losartan; Male; Primary Prevention; Prognosis; Tetrazoles; Treatment Outcome

2001
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
    Journal of hypertension, 2002, Volume: 20, Issue:2

    Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Uric Acid

2002
Preventing nephropathy in patients with type 2 diabetes.
    Managed care interface, 2002, Volume: 15, Issue:1

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Management; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Tetrazoles; Treatment Outcome; United States

2002
Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.
    Electrophoresis, 2002, Volume: 23, Issue:2

    Topics: Acrylates; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Chemical Fractionation; Electrophoresis, Capillary; Imidazoles; Irbesartan; Losartan; Mathematical Computing; Molecular Structure; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2002
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hyperkalemia; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles

2002
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Losartan; Oxidative Stress; Tetrazoles

2002
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:5

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Middle Aged; Receptor, Angiotensin, Type 1; Tetrazoles

2002
Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.
    European journal of pharmacology, 2002, May-03, Volume: 442, Issue:1-2

    Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Cholesterol; Cholesterol, Dietary; Coronary Vessels; Dose-Response Relationship, Drug; Hypercholesterolemia; In Vitro Techniques; Irbesartan; Lipoproteins, HDL; Lipoproteins, LDL; Losartan; Male; Mesenteric Arteries; Nitroprusside; Norepinephrine; Potassium Chloride; Rabbits; Receptor, Angiotensin, Type 1; Serotonin; Tetrazoles; Time Factors; Vasodilator Agents

2002
A population-based European cohort study of persistence in newly diagnosed hypertensive patients.
    Journal of human hypertension, 2002, Volume: 16, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Cohort Studies; Europe; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Receptors, Angiotensin; Retreatment; Tetrazoles; Treatment Failure

2002
Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
    Journal of hypertension, 2002, Volume: 20, Issue:9

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Electric Stimulation; In Vitro Techniques; Irbesartan; Losartan; Norepinephrine; Osmolar Concentration; Rabbits; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Sympatholytics; Synaptic Transmission; Telmisartan; Tetrazoles

2002
Irbesartan substitution for valsartan or losartan in treating hypertension.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:12

    Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan

2002
Control of dendritic cell differentiation by angiotensin II.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Cells, Cultured; Dendritic Cells; Endocytosis; Hematopoietic Stem Cells; Humans; Irbesartan; Losartan; Lymphocyte Activation; Mice; Models, Biological; Monocytes; Phenotype; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles

2003
Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:3

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Binding Sites; Binding, Competitive; Biphenyl Compounds; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Irbesartan; Lipoproteins, LDL; Losartan; Monocytes; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Tetrazoles

2003
A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.
    Biochemical pharmacology, 2003, Apr-15, Volume: 65, Issue:8

    Topics: Angiotensin Receptor Antagonists; Animals; Binding Sites; Biphenyl Compounds; CHO Cells; Cold Temperature; Computer Simulation; Cricetinae; Imidazoles; Irbesartan; Kinetics; Losartan; Models, Biological; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles; Thermodynamics; Transfection

2003
Cardiology patient page. Angiotensin receptor blockers.
    Circulation, 2003, Jun-24, Volume: 107, Issue:24

    Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2003
Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
    Journal of cardiovascular pharmacology, 2003, Volume: 42, Issue:1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Antagonism; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Losartan; Muscle Contraction; Muscle, Smooth, Vascular; Receptors, Thromboxane A2, Prostaglandin H2; Saphenous Vein; Tetrazoles; Valine; Valsartan

2003
[Fast-acting sartan. High blood pressure therapy without long waiting time].
    MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Rats; Tetrazoles; Time Factors; Valine; Valsartan

2003
[Dosage equivalents of AT1-receptor antagonists available in Germany].
    Deutsche medizinische Wochenschrift (1946), 2003, Oct-31, Volume: 128, Issue:44

    Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan

2003
Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 309, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium; Desoxycorticosterone; Disease Models, Animal; Endothelin A Receptor Antagonists; Humans; Hypertension; Irbesartan; Losartan; Male; Oxazoles; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Sodium; Sulfonamides; Tetrazoles

2004
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5

    Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain

2004
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
    Circulation, 2004, May-04, Volume: 109, Issue:17

    Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Differentiation; Genes, Reporter; Imidazoles; Insulin Resistance; Irbesartan; Losartan; Luciferases; Mice; PC12 Cells; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; Telmisartan; Tetrazoles; Thiophenes; Transcription Factors; Transfection

2004
Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II.
    Nephron. Experimental nephrology, 2005, Volume: 100, Issue:1

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cell Culture Techniques; Diabetic Nephropathies; Glucose; Humans; Irbesartan; Kidney Glomerulus; Losartan; Oxidants; Superoxide Dismutase; Superoxides; Tetrazoles

2005
Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
    Journal of hypertension, 2005, Volume: 23, Issue:10

    Topics: Acrylates; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Imidazoles; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Inbred SHR; Sympathetic Fibers, Postganglionic; Sympatholytics; Tetrazoles; Thiophenes; Time Factors; Treatment Outcome

2005
Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis.
    Journal of chromatography. A, 2006, Jan-13, Volume: 1102, Issue:1-2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Electrophoresis, Capillary; Ethylene Glycols; Humans; Irbesartan; Losartan; Methacrylates; Receptors, Angiotensin; Sensitivity and Specificity; Telmisartan; Tetrazoles

2006
Effects of losartan and irbesartan administration on brain angiotensinogen mRNA levels.
    European journal of pharmacology, 2005, Dec-28, Volume: 528, Issue:1-3

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Biphenyl Compounds; Brain; Dose-Response Relationship, Drug; Intubation, Gastrointestinal; Irbesartan; Losartan; Male; Rats; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Time Factors

2005
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
    Journal of hypertension, 2006, Volume: 24, Issue:9

    Topics: Adipogenesis; Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Irbesartan; Lipoprotein Lipase; Losartan; Luciferases; Male; Pioglitazone; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones

2006
Liquid chromatographic determination of irbesartan in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Apr-01, Volume: 848, Issue:2

    Topics: Biphenyl Compounds; Chromatography, High Pressure Liquid; Drug Stability; Ether; Freezing; Humans; Irbesartan; Losartan; Methylene Chloride; Molecular Structure; Reproducibility of Results; Sodium Hydroxide; Spectrometry, Fluorescence; Tetrazoles

2007
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
    Pharmacotherapy, 2007, Volume: 27, Issue:4

    Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; British Columbia; Drug Prescriptions; Female; Heart Failure; Hospital Information Systems; Humans; Irbesartan; Losartan; Male; Ontario; Proportional Hazards Models; Quebec; Retrospective Studies; Survival Analysis; Survival Rate; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2007
Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
    Current medical research and opinion, 2008, Volume: 24, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cost-Benefit Analysis; Drug Costs; Humans; Hypertension; Irbesartan; Losartan; Markov Chains; Tetrazoles; Valine; Valsartan

2008
Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:9

    Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Approval; Humans; Irbesartan; Losartan; Tetrazoles; Time Factors; United States; Valine; Valsartan

2008
Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers?
    Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Carotid Arteries; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan

2008
Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard.
    Journal of pharmaceutical and biomedical analysis, 2009, Apr-05, Volume: 49, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Calibration; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Irbesartan; Losartan; Quality Control; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles

2009
HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies.
    Biomedical chromatography : BMC, 2009, Volume: 23, Issue:6

    Topics: Acetonitriles; Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chromatography, High Pressure Liquid; Humans; Irbesartan; Losartan; Male; Reproducibility of Results; Sample Size; Sensitivity and Specificity; Spectrometry, Fluorescence; Tetrazoles; Time Factors; Young Adult

2009
Angiotensin II receptor blockers in pregnancy: a report of five cases.
    Reproductive toxicology (Elmsford, N.Y.), 2009, Volume: 28, Issue:1

    Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Female; Gestational Age; Humans; Hypertension; Infant, Newborn; Irbesartan; Kidney Diseases; Losartan; Oligohydramnios; Pregnancy; Pregnancy Complications, Cardiovascular; Premature Birth; Retrospective Studies; Risk Assessment; Slovenia; Tetrazoles

2009
Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan.
    Journal of separation science, 2009, Volume: 32, Issue:14

    Topics: Administration, Oral; Biphenyl Compounds; Calibration; Chromatography, Liquid; Humans; Irbesartan; Linear Models; Losartan; Male; Reference Values; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrazoles; Time Factors

2009
Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.
    Cardiovascular diabetology, 2009, Jun-22, Volume: 8

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Biphenyl Compounds; Diabetes Mellitus, Experimental; In Vitro Techniques; Irbesartan; Losartan; Male; Rats; Rats, Wistar; rho-Associated Kinases; Tetrazoles; Up-Regulation; Vasoconstriction

2009
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
    Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:10

    Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Fumarates; Health Care Costs; Humans; Hypertension; Irbesartan; Losartan; Quality-Adjusted Life Years; Tetrazoles

2009
Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.
    Life sciences, 2010, Jan-02, Volume: 86, Issue:1-2

    Topics: Adenosine Triphosphatases; Angiotensin II Type 1 Receptor Blockers; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Benzoates; Biological Transport; Biphenyl Compounds; Caco-2 Cells; Calcium Channel Blockers; Cardiotonic Agents; Cell Membrane; Digoxin; Drug Interactions; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Verapamil

2010
Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:5

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arthritis, Experimental; Biphenyl Compounds; Cardiovascular Diseases; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Hypertrophy; Irbesartan; Losartan; Male; Oxidative Stress; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk Reduction Behavior; Tetrazoles; Vasoconstrictor Agents

2010
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
    Biopharmaceutics & drug disposition, 2010, Volume: 31, Issue:2-3

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes

2010
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2011, Volume: 12, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Female; Greece; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Male; Markov Chains; Middle Aged; Models, Economic; Quality of Life; Sex Factors; Tetrazoles; Valine; Valsartan

2011
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:6

    Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan

2010
A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:10

    Topics: 3T3-L1 Cells; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cell Line; Cells, Cultured; Chemokine CCL2; Chlorocebus aethiops; COS Cells; Endothelium, Vascular; Fibroblasts; HEK293 Cells; Humans; Irbesartan; Kidney; Losartan; Mice; NF-kappa B; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles

2010
Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade.
    Biochemical and biophysical research communications, 2011, Jun-03, Volume: 409, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Brain Ischemia; Germanium; Irbesartan; Losartan; Male; Mice; Mice, Inbred C57BL; Organometallic Compounds; Propionates; Receptors, CCR2; Signal Transduction; Tetrazoles

2011
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:3

    Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan

2012
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Black or African American; Blood Pressure; Diabetes Mellitus; Electronic Health Records; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Obesity; Primary Health Care; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People; Young Adult

2011
Subtle issues in model specification and estimation of marginal structural models.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:3

    Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Tetrazoles; Valine; Valsartan

2012
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
    Journal of the American Heart Association, 2013, Apr-22, Volume: 2, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Heart; Hepatocyte Growth Factor; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Kidney; Losartan; Mice; Mice, Knockout; Myocardium; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles

2013
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
    Cardiovascular journal of Africa, 2013, Volume: 24, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Catalase; Disease Models, Animal; Hypertension; Irbesartan; Losartan; Male; Myocardium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Superoxide Dismutase; Tetrazoles; Time Factors

2013
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Sep-03, Volume: 185, Issue:12

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Stroke; Telmisartan; Tetrazoles; Treatment Outcome

2013
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: implications in heart failure.
    European journal of pharmacology, 2013, Oct-15, Volume: 718, Issue:1-3

    Topics: Aldehyde Dehydrogenase; Angiotensin II; Animals; Biphenyl Compounds; Catalase; Enzyme Activation; Heart Failure; Hyperglycemia; Irbesartan; Losartan; Monoamine Oxidase; Myocytes, Cardiac; Rats; Tetrazoles

2013
Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
    Journal of clinical hypertension (Greenwich, Conn.), 2013, Volume: 15, Issue:12

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Substitution; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:5

    Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Proportional Hazards Models; Registries; Retrospective Studies; Survival Rate; Taiwan; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Bradykinin; Cardiotonic Agents; Heart; Hemodynamics; In Vitro Techniques; Irbesartan; Ischemic Postconditioning; Losartan; Male; Mitogen-Activated Protein Kinases; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Systole; Tetrazoles

2014
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
    Diabetes, 2014, Volume: 63, Issue:8

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles

2014
Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.
    Diabetes, 2014, Volume: 63, Issue:8

    Topics: Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Tetrazoles

2014
A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide.
    International journal of pharmaceutics, 2015, Jan-15, Volume: 478, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Bile Acids and Salts; Biphenyl Compounds; HEK293 Cells; Humans; Irbesartan; Losartan; Organic Anion Transporters, Sodium-Dependent; Symporters; Tetrazoles

2015
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:9

    Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Prognosis; Renin-Angiotensin System; Risk Factors; Tetrazoles

2016
Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents.
    Drug research, 2016, Volume: 66, Issue:5

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzbromarone; Biphenyl Compounds; Cells, Cultured; Glucose Transport Proteins, Facilitative; Human Umbilical Vein Endothelial Cells; Humans; Irbesartan; Losartan; Monocarboxylic Acid Transporters; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Tetrazoles; Uric Acid; Uricosuric Agents

2016
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
    Journal of hypertension, 2016, Volume: 34, Issue:6

    Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Oxadiazoles; Self Care; Telmisartan; Tetrazoles; Time Factors; Valsartan

2016
Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2016, Volume: 38, Issue:3

    Topics: Acrylates; Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Republic of Korea; Retrospective Studies; Risk Factors; Tetrazoles; Thiophenes; Valsartan

2016
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
    Journal of translational medicine, 2016, 07-05, Volume: 14, Issue:1

    Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Irbesartan; Losartan; Male; Metabolome; Middle Aged; Models, Molecular; Tetrazoles

2016
Protolytic Equilibria of Sartans in Micellar Solutions of Differently Charged Surfactants.
    Journal of pharmaceutical sciences, 2016, Volume: 105, Issue:8

    Topics: Biphenyl Compounds; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Irbesartan; Losartan; Micelles; Molecular Structure; Protons; Solubility; Solutions; Solvents; Surface-Active Agents; Tetrazoles; Valsartan; Water

2016
Complex formation equilibria of Cu
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Jan-15, Volume: 97

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Coordination Complexes; Copper; Humans; Irbesartan; Losartan; Tetrazoles; Zinc

2017
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
    Naunyn-Schmiedeberg's archives of pharmacology, 2017, Volume: 390, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood-Brain Barrier; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Irbesartan; Losartan; Male; Neuroprotective Agents; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Stroke; Tetrazoles; Tissue Distribution

2017
Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:8

    Topics: Adult; Asian People; Biphenyl Compounds; Blood Glucose; Carbamates; Cells, Cultured; China; Dose-Response Relationship, Drug; Drug Interactions; Genotype; Healthy Volunteers; Humans; Imidazoles; Irbesartan; Liver-Specific Organic Anion Transporter 1; Losartan; Male; Piperidines; Polymorphism, Single Nucleotide; Tetrazoles; Valsartan; Young Adult

2018
Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
    Naunyn-Schmiedeberg's archives of pharmacology, 2019, Volume: 392, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Kidney; Kynurenic Acid; Losartan; Male; Rats, Wistar; Telmisartan; Tetrazoles; Transaminases; Valsartan

2019
Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
    The New England journal of medicine, 2019, Apr-25, Volume: 380, Issue:17

    Topics: Angiotensin II Type 1 Receptor Blockers; Dimethylnitrosamine; Drug Contamination; Drug Recalls; Humans; Hypertension; Irbesartan; Losartan; Nitrosamines; United States; United States Food and Drug Administration; Valsartan

2019
HPLC method transfer study for simultaneous determination of seven angiotensin II receptor blockers.
    Journal of separation science, 2020, Volume: 43, Issue:8

    Topics: Acrylates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chlorthalidone; Chromatography, High Pressure Liquid; Hydrochlorothiazide; Imidazoles; Irbesartan; Losartan; Molecular Structure; Software; Tablets; Tetrazoles; Thiophenes; Valsartan

2020
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020, Jun-01, Volume: 1146

    Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan

2020
Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:6

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Female; Humans; Hyperuricemia; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Time Factors; Uric Acid

2020
Differential Scanning Calorimetry (DSC) on Sartan/Cyclodextrin Delivery Formulations.
    Methods in molecular biology (Clifton, N.J.), 2021, Volume: 2207

    Topics: Calorimetry, Differential Scanning; Cyclodextrins; Drug Carriers; Irbesartan; Losartan

2021
Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report.
    Arteriosclerosis, thrombosis, and vascular biology, 2022, Volume: 42, Issue:10

    Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupture; Dilatation, Pathologic; Disease Models, Animal; Irbesartan; Losartan; Lysine; Male; Mice; Mice, Inbred C57BL; Protein-Lysine 6-Oxidase; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System

2022
Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism.
    Water research, 2023, Feb-01, Volume: 229

    Topics: Angiotensin II Type 1 Receptor Blockers; Biofilms; Blood Pressure; Humans; Irbesartan; Losartan; Sewage; Valsartan; Wastewater; Water Pollutants, Chemical; Water Purification

2023
Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
    Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Brazil; Carcinogens; Chromatography, High Pressure Liquid; Humans; Irbesartan; Losartan; Nitrosamines; Pharmaceutical Preparations; Tandem Mass Spectrometry; Telmisartan; Valsartan

2023
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
    BMJ open, 2023, 04-17, Volume: 13, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Canada; Cohort Studies; Denmark; Humans; Hypertension; Irbesartan; Losartan; Retrospective Studies; Tetrazoles; United Kingdom; Valsartan

2023
A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:6

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Germany; Humans; Hypertension; Irbesartan; Losartan; Nitrosamines; Valsartan

2023
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
    Medicine, 2023, Nov-17, Volume: 102, Issue:46

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan

2023